Full TitlePhase 1a/b Trial of Exercise as Interception Therapy for Primary High-Risk Cancer
The purpose of this study is to examine the effect of exercise on circulating tumor DNA (ctDNA) in the blood of people who were previously treated for colorectal cancer and who exercise 60 minutes a week or less. ctDNA are dead tumor cells that get broken down and are released into the bloodstream. The presence of ctDNA in the blood can help predict the risk of cancer coming back.
Researchers think that exercise may be able to prevent cancer from returning by lowering ctDNA levels. In this study, they are exploring how aerobic exercise can reduce the level of ctDNA in the blood. During the study, they will try to find the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer.
Participants in this study will engage in walking sessions three to six times a week for a total of 90-375 minutes each week. They will participate in these walking sessions for 24 weeks. The walking sessions will be on a treadmill sent to their homes. They can also complete the sessions at Memorial Sloan Kettering Cancer Center.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- This study is for people who completed treatment for stage II or III colorectal cancer and have no evidence of disease.
- Participants should be exercising only 60 minutes or less per week upon entering the study.
- People taking hormonal cancer therapies and those with type 2 diabetes may not participate.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Lee Jones at 646-888-8103.